移至標頭
移至導覽
移至內部
移至註腳
登入
幫助
中文（繁體）
Research Resources
CUHK UPDates
Theses
Experts List
User Guides
About Us
List of Researchers
> Professor Lam CHAN
主頁
研究成果
研究人員專頁
學系學部專頁
研究範圍
Professor CHAN Lam
Personal Information
Position and Department
Professor
,
Department of Clinical Oncology
ORCiD
0000-0001-8998-5480
ResearcherID
F-9149-2011
CUHK Research Outputs
1 of 7
Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease
(
2022
)
CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein
(
2022
)
Comparison of chemoembolization, radioembolization, and transarterial ethanol ablation for huge hepatocellular carcinoma (≥10cm) in tumour response and long-term survival outcome
(
2022
)
Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
(
2022
)
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
(
2022
)
Personalized treatment for hepatocellular carcinoma: Current status and future perspectives
(
2022
)
Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial
(
2022
)
Single-molecule Sequencing Enables Long Cell-free DNA Detection and Direct Methylation Analysis for Cancer Patients
(
2022
)
Sirtuin 7 super-enhancer drives epigenomic reprogramming in hepatocarcinogenesis
(
2022
)
The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021
(
2022
)
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
(
2022
)
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240
(
2021
)
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma
(
2021
)
Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology
(
2021
)
A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
(
2021
)
A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
(
2021
)
Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis
(
2021
)
Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade
(
2021
)
CircRTN4 Promotes Pancreatic Cancer progression through a novel circRNA-miRNA-lncRNA pathway and Stabilizing Epithelial-Mesenchymal Transition Protein
(
2021
)
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
(
2021
)
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
(
2021
)
Genome-wide detection of cytosine methylation by single molecule real-time sequencing
(
2021
)
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
(
2021
)
Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection
(
2021
)
Hyperprogression in hepatocellular carcinoma: Illusion or reality?
(
2021
)
Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma
(
2021
)
Systemic treatment of hepatocellular carcinoma: An EASL position paper
(
2021
)
Targeting PPAR signaling Overcomes Adaptive Resistance to Immune Checkpoint Blockade by Abrogating Immunosuppression and T Cell Exhaustion
(
2021
)
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
(
2020
)
Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240
(
2020
)
Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC)
(
2020
)
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
(
2020
)
CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942
(
2020
)
Contaminated and misidentified cell lines commonly use in cancer research
(
2020
)
Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars
(
2020
)
Detection and characterization of jagged ends of double-stranded DNA in plasma
(
2020
)
Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma
(
2020
)
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
(
2020
)
Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma
(
2020
)
Endoscopic ultrasound-guided cyanoacrylate injection to prevent rebleeding in hepatocellular carcinoma patients with variceal hemorrhage
(
2020
)
Enhancer reprogramming by selective HDAC8 inhibition potentiates T cell infiltration and durable antitumor efficacy of PD-L1 blockade
(
2020
)
Enhancer reprogramming by selective HDAC8 inhibition potentiates tumor remission and durable benefit by PD-L1 blockade
(
2020
)
Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma
(
2020
)
Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study
(
2020
)
Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC
(
2020
)
Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study
(
2020
)
Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory-wide cohort study
(
2020
)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
(
2020
)
Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
(
2020
)
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach
(
2020
)
分享連結
Last updated on 2021-02-08 at 06:30
分享連結
您的名稱*
您的電子郵件*
收件者名稱*
收件者電子郵件*
訊息
Auxilliary Information
不會儲存任何資訊或與任何第三方分享資訊。
Cancel
Our policy towards the use of cookies
All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Ok to Continue
Cookie Policy
